Orphine Opioids: Complete Cychlorphine, Chlorphine, Spirochlorphine Toxicology & Safety Monograph

Orphine Opioids: Complete Cychlorphine, Chlorphine, Spirochlorphine Toxicology & Safety Monograph

Emergency opioid warning: Orphines are opioid-receptor agonists. If someone is unresponsive, cannot be awakened, has slow/irregular/stopped breathing, blue or gray lips/skin, gurgling/choking, or collapses after an unknown pill, powder, or opioid-like product, call emergency services and give naloxone if available. Do not wait for chemical confirmation.

Quick answer

Orphines are a rapidly emerging family of potent synthetic opioids, usually based on substituted piperidine benzimidazolone structures. Important members include brorphine, chlorphine, N-propionitrile chlorphine (cychlorphine), spirochlorphine, spirobrorphine, 5,6-dichloro desmethylchlorphine (SR-17018), and 5,6-dichloro brorphine (SR-14968).

The family is historically linked to pharmaceutical opioid-discovery chemistry from the 1960s–1970s, but the modern illicit-market wave began with brorphine around 2019–2020 and diversified sharply in 2024–2026.

The best current human evidence centers on cychlorphine. By May 2026, UNODC reported cychlorphine from 10 countries, 182 drug seizures, and 78 fatal overdoses. CFSRE had previously reported cychlorphine in 25 fatal-overdose blood specimens, including 11 where it was the only opioid detected, while DEA's August 2026 scheduling record reported 49 DEA TOX fatalities with cychlorphine identified. These are serious exposure signals, but a detected drug is not automatically the sole cause of every death.

Human case reports also document opioid toxidromes with respiratory depression and naloxone response after analytically confirmed cychlorphine exposure.

The family remains much less characterized than fentanyl or conventional opioids. There is no validated recreational dose, universal potency ratio, family-wide withdrawal timeline, or fatal blood concentration.

Identity and family map

The word orphine is a family label, not a potency unit.

History: old medicinal chemistry, new drug-market role

The chemical lineage reaches back to pharmaceutical opioid research involving compounds such as bezitramide and R-6890/spirochlorphine.

Brorphine was synthesized in modern NPS research in 2018 and appeared in the recreational drug supply around 2019. It became a major non-fentanyl synthetic opioid signal in 2020 and was internationally controlled in 2022.

The next wave accelerated in 2024–2026. CFSRE first detected cychlorphine in 2024. Spirochlorphine was confirmed in CFSRE drug material in 2025. By early 2026, multiple orphine analogues were appearing across North America and Europe.

CFSRE and UNODC both describe increased orphine detection as nitazene availability changed after broader precursor/core-structure controls. This is evidence of market substitution, not proof that one specific law mechanically caused every orphine sale.

Pharmacology

Mu-opioid receptor

The clearest shared pharmacology is mu-opioid receptor (MOR) agonism.

A 2024 comparative study of brorphine, orphine, fluorphine, chlorphine and iodorphine found nanomolar MOR binding and strong agonist activity across receptor assays. Potency varied between compounds and between experimental systems.

Cychlorphine has also shown very high MOR activity in preclinical work. UNODC summarizes recent data as showing potency exceeding fentanyl in some assays and profound respiratory/cardiovascular depression in mice at lower doses than fentanyl.

Those findings establish a high-hazard opioid mechanism. They do not establish a safe human conversion such as "X mg cychlorphine = Y mg fentanyl."

Why one potency number is misleading

Potency can refer to:

• receptor binding affinity;
• G-protein signaling;
• beta-arrestin signaling;
• antinociception;
• respiratory depression;
• a specific species and administration route.

A ratio from one endpoint cannot be promoted into a universal human potency ratio.

Metabolism and pharmacokinetics

Human pharmacokinetic data for most emerging orphines are sparse or absent.

Brorphine is the best-characterized family member analytically. Human forensic urine and blood studies have identified multiple metabolites; one study found 14 urinary metabolites and four in blood, with N-oxidation prominent in vivo.

For cychlorphine, chlorphine, spirochlorphine and newer analogues, controlled human absorption, half-life, clearance, accumulation and active-metabolite profiles remain inadequately characterized.

Therefore:

• forum duration reports are not human PK;
• brorphine metabolism should not automatically be copied onto cychlorphine;
• an unknown analogue cannot be assigned another orphine's half-life.

Human evidence

Cychlorphine overdose

A 2026 medical-toxicology case described a woman in her 20s who believed she had taken alprazolam. She developed unresponsiveness and respiratory depression and received 6 mg intranasal naloxone before ED arrival. Comprehensive serum testing confirmed cychlorphine along with bromazolam and other substances. This is direct evidence of a clinically significant opioid toxidrome in a mislabeled/counterfeit-drug context, while the co-exposures limit single-drug attribution.

A separate Clinical Toxicology report documented a nonfatal cychlorphine overdose, strengthening the direct human evidence.

Fatality surveillance

CFSRE reported cychlorphine in 25 blood specimens from fatal overdoses, most submitted in late 2025 and early 2026; it was the sole opioid detected in 11 of those cases.

UNODC later reported 78 fatal-overdose detections globally by May 2026.

DEA's August 27, 2026 temporary scheduling order reported 49 DEA TOX fatalities with N-propionitrile chlorphine identified.

These datasets overlap in unknown ways and should not be added together to create a fake cumulative death count.

Brorphine human evidence

Brorphine has a longer forensic history, including published fatal intoxication reports, LC-MS toxicology casework, counterfeit-product detections, and metabolism studies.

The family's evidence base is therefore heterogeneous: brorphine has several years of casework; cychlorphine has rapidly accumulating 2025–2026 evidence; many newer analogues remain mostly preclinical/forensic.

Acute toxicity and overdose

Expected and documented severe opioid effects include:

• profound sedation;
• miosis;
• respiratory depression;
• unresponsiveness;
• hypoxia;
• bradycardia;
• hypotension or cardiovascular instability;
• cardiac arrest;
• death.

Unknown co-drugs are common. Counterfeit benzodiazepines, fentanyl, stimulants and other NPS can coexist in the same exposure.

Naloxone

Naloxone is appropriate for suspected orphine opioid overdose.

Human cychlorphine cases demonstrate clinical naloxone use. The evidence does not establish one universal "orphine naloxone dose." Repeat treatment and medical observation may be necessary because potency, amount, duration and co-drugs are uncertain.

Interactions and polysubstance risk

The most concerning combinations are other CNS/respiratory depressants:

• fentanyl or other opioids;
• benzodiazepines;
• alcohol;
• xylazine-containing mixtures;
• gabapentinoids;
• sedative-hypnotics.

Stimulants do not "cancel out" opioid respiratory depression and can add cardiovascular risk.

Because most real-world NPS toxicology is polysubstance, absence of an orphine-specific interaction trial is not evidence of a safe combination.

Tolerance, dependence and withdrawal

What is directly established

The emerging orphine literature is much stronger on overdose and forensic detection than on prospective human dependence/withdrawal.

What is strongly class-supported

Repeated MOR agonist exposure can produce:

• tolerance;
• physical dependence;
• opioid withdrawal;
• craving and compulsive use;
• loss-of-tolerance overdose risk after abstinence.

These are credible concerns for potent orphines. But there is no validated cychlorphine-specific or family-wide withdrawal timeline.

Physical dependence vs opioid use disorder

Physical dependence means withdrawal occurs when exposure stops. Opioid use disorder is a broader behavioral syndrome that can involve craving, inability to cut down, repeated hazardous use, continued use despite harm, or interference with responsibilities.

A person can be exposed unintentionally through a counterfeit pill and still develop physical dependence.

Treatment and support

There is no orphine-specific approved addiction treatment.

When a person has an opioid toxidrome, opioid withdrawal, or signs of opioid use disorder after an unknown synthetic opioid, clinicians can use established opioid-care frameworks.

Evidence-based OUD medications include buprenorphine and methadone; extended-release naltrexone can be appropriate after adequate opioid abstinence in selected patients. This page does not provide self-induction or taper schedules.

U.S. resources:

• FindTreatment.gov
• SAMHSA National Helpline: 1-800-662-HELP (4357)

Emergency overdose or severe medical instability requires emergency services.

Testing and analytical toxicology

Routine drug screens can miss orphines.

UNODC specifically warns that fentanyl and nitazene test strips do not detect orphine analogues reliably. A negative fentanyl strip therefore cannot establish that an unknown sample is opioid-free.

Laboratory confirmation generally requires methods such as:

• LC-MS/MS;
• LC-HRMS / QTOF;
• targeted or non-targeted high-resolution workflows;
• updated spectral libraries;
• appropriate reference standards.

The analytical challenge is dynamic: new analogues can appear before laboratories have validated standards or added them to routine panels.

Counterfeit and mislabeled product risk

Human cychlorphine evidence includes a person who reported taking alprazolam, illustrating the central problem: the user may not know an opioid is present.

Brorphine has also been reported in counterfeit opioid tablets and mixed illicit products.

Therefore, appearance, imprint, flavor, branding or seller description cannot establish chemical identity.

Forensic interpretation

A detected orphine in a death is important evidence of exposure, but causal interpretation must account for:

• co-detected fentanyl, other opioids, benzodiazepines or stimulants;
• tolerance;
• specimen type;
• postmortem redistribution;
• analytical method and reference standard;
• active metabolites;
• timing;
• underlying disease.

There is no universal "fatal cychlorphine level" or "fatal orphine level." Low concentrations can occur with highly potent opioids, but a single number cannot be converted into a personal lethal dose.

Epidemiology and market transition

CFSRE reported rapid growth of cychlorphine positivity beginning in mid-2025. Its January 2026 alert described 25 fatal-overdose blood specimens and more than 100 tentative NMS Labs toxicology detections.

A broader 2026 CFSRE/Colombo Plan data-mining effort found 2024–2025 signals for multiple family members, including cychlorphine, spirochlorphine, chlorphine, brorphine and 5,6-dichloro desmethylchlorphine.

UNODC reported 11 orphine analogues across 14 countries by early 2026. By May, cychlorphine was the most commonly reported member.

This is a rapidly changing family rather than a single-drug outbreak.

U.S. and international legal status

Legal status must be checked by exact molecule and date.

United States

DEA temporarily placed these four compounds in Schedule I effective August 27, 2026 through August 27, 2028, unless extended or superseded:

• 5,6-dichloro brorphine (SR-14968);
• 5,6-dichloro desmethylchlorphine (SR-17018);
• N-propionitrile chlorphine (cychlorphine);
• spirochlorphine (R-6890).

Brorphine itself has an earlier control history and international scheduling history. Other emerging orphines may have different status.

International

Brorphine was placed under international control in 2022. UNODC EWA now tracks the wider orphine family and country-level detections.

Do not infer that every molecule ending in "-orphine" has identical legal status.

Special populations

No adequate controlled studies define orphine safety in pregnancy, breastfeeding, adolescents, older adults, respiratory disease, seizure disorders, or serious hepatic/renal disease.

Risk is especially concerning for opioid-naive people, people with sleep apnea/respiratory disease, those recently abstinent from opioids, and those taking other depressants.

Myths and evidence corrections

"Orphines are just nitazenes with a new name."
No. They are chemically distinct opioid families.

"Cychlorphine is exactly 10× fentanyl in people."
Not established. That shorthand comes from preclinical pharmacology and cannot be converted into a human dose ratio.

"A negative fentanyl strip means no dangerous opioid."
False. Orphines may not be detected.

"Naloxone does not work because this is a new opioid."
False. Human cychlorphine overdose cases document naloxone use; naloxone remains appropriate for suspected opioid toxicity.

"All 78 cychlorphine fatal detections prove cychlorphine acted alone."
No. Detection, contribution and sole causation are distinct forensic claims.

"No withdrawal studies means no dependence risk."
False. Potent MOR agonism makes opioid dependence biologically credible; the unknown is the exact human incidence and timeline.

Evidence ledger

Related evidence

• Cychlorphine / N-propionitrile chlorphine
• Brorphine
• Nitazene opioids
• Designer synthetic opioids beyond nitazenes
• Research chemicals & NPS evidence map
• Substance Use, Dependence & Harm Reduction hub

Bottom line

Orphines are a fast-expanding synthetic-opioid family whose public-health importance rose sharply in 2025–2026.

The strongest current signal is cychlorphine: analytically confirmed nonfatal overdose, dozens of fatal toxicology detections, international spread, and evidence of counterfeit/mislabeled exposure. Brorphine provides the older proof-of-concept that this scaffold can move rapidly from medicinal chemistry into fatal NPS casework.

The evidence is already strong enough to treat unknown orphine exposure as a serious opioid emergency. It is not strong enough to justify consumer dose charts, universal potency rankings, or confident withdrawal timelines.

That combination—high hazard plus incomplete characterization—is exactly why the family belongs in a safety-first reference library.